CRBP
INSIDER BUYINSIDER SELLCorbus Pharmaceuticals Holdings, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveCorbus achieved a major milestone with positive CANYON-1 Phase 1b data for CRB-913 showing 5% weight loss at 60mg with no plateau and improved CNS safety profile versus prior cannabinoid candidates, while simultaneously advancing CRB-701 into a registrational oncology study and bolstering leadership. However, the company is burning ~$35M per quarter with significant operating expense growth, and analyst price target disagreement (ranging $35–$88) suggests substantial execution risk ahead.
Red flags
- •Quarterly net loss of $35.0M ($1.81/share) with accelerating operating expenses (+$17M QoQ); cash burn trajectory raises financing risk
- •Analyst price target dispersion of ~$53 range ($35–$88) indicates high uncertainty; Mizuho downgrade post-CANYON-1 suggests not all Street views are constructive
- •CRB-913 data is early-stage Phase 1b (n=240, 12-week duration); efficacy/safety in larger Phase 2b studies and long-term durability remain unproven
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Citadel Advisors | SC 13G/A | — | 1.1% | -42.1% vs SPY -42.0% abs | 2026-08-14 | ↗ |